Francesco Bertoni

74PUBLICATIONS
214CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (74)

|Jun 26, 2026
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

|Jun 12, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.

|Jun 01, 2026
Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.

|May 29, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.

|Feb 09, 2026
OSTM1 is a ubiquitin E3 ligase that suppresses B-cell malignancy by activating the cAMP/PKA/CREB pathway.

Muhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen

Pageof 13

Frequent Collaborators

30 joint publications

Luciano Cascione

13 joint publications

Chiara Tarantelli

10 joint publications

Filippo Spriano

10 joint publications

Emanuele Zucca